Neelakantan et al., NNMT inhibition reverses diet-induced obesity in mice (2018) Babula et al., NNMT inhibition mitigates obesity-related metabolic dysfunction: fat mass, glucose tolerance, hepatic steatosis, pharmacokinetics and off-target screen (Diabetes Obes Metab, 2024) Dimet-Wiley et al., NNMT inhibition mimics and boosts exercise-mediated muscle improvements in aged mice (Sci Rep, 2024) NNMT inhibition and muscle function in aged mice (2019) Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (2022): the diet-switch combination study Awosemo et al., rat pharmacokinetics of 5-amino-1MQ (2021) NNMT in metabolism and disease: review Sigma-Aldrich: 5-Amino-1MQ iodide product data (CAS 42464-96-0) FDA: bulk drug substances used in compounding under section 503A Disclaimer: Informational and research purposes only, not medical advice
Supporters point to a large real-world usage record with few reported problems
Does it work on its own
Doctors would write prescriptions to a compounding pharmacy for BPC-157 (often alongside other peptides like TB-500, CJC-1295, etc.), and patients could receive the drug despite its unapproved status
A blood test is initially carried out to determine a deficiency before a treatment plan is devised and implemented
PMC 7653199